Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis

Launched by TIANJIN MEDICAL UNIVERSITY SECOND HOSPITAL · Aug 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to tailor chemotherapy treatments for men with prostate cancer that has spread to other organs. Researchers are creating a special model called an "organoid chip" using tissue samples from patients. This model will help them test how well different chemotherapy drugs work on each patient’s cancer, aiming to find the most effective treatment plan for each individual.

To qualify for this trial, participants must be men aged 18 or older who have been diagnosed with prostate cancer that has metastasized, meaning it has spread to other parts of the body. They should also have good overall health, particularly in terms of liver and kidney function, and be able to provide tissue samples from surgery or a biopsy. Those who join the study will undergo testing to see how their cancer responds to various chemotherapy drugs, helping to personalize their treatment. It's important for potential participants to be aware that those with certain serious health conditions or who cannot provide tissue samples may not be eligible to take part in this research.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with visceral metastasis of prostate cancer diagnosed clinically or pathologically;
• • 2. Age ≥ 18 years old;
• • 3. ECOG score ≤ 2 points or ECOG score 3-4 points due to tumor progression;
• • 4. Normal liver and kidney function, serum transaminase ALT\<66 U/L, AST\<36 U/L, total bilirubin\<22 umol/L, creatinine\<106 umol/L, urea nitrogen\<6.1 mmol/L; Normal bone marrow function: neutrophil count ≥ 1800/mm3 and platelet count ≥ 100000/mm3;
• • 5. Can obtain surgical or biopsy samples;
• • 6. Patients voluntarily join this study and sign an informed consent form.
• Exclusion Criteria:
• • 1. Patients with severe heart, liver, kidney, and peripheral nervous system diseases, as well as autoimmune diseases such as hyperthyroidism and hypothyroidism; Systemic lupus erythematosus, etc;
• • 2. Patients who are unable to obtain tissue samples;
• • 3. Subjects with active pulmonary tuberculosis (TB);
• • 4. Subjects who are preparing for or have previously undergone tissue/organ transplantation;
• • 5. Exclusion criteria are not listed, but the researchers believe that patients who are not suitable to participate in this clinical study.